The news comes in advance of a meeting of a key FDA advisory committee to examine how the composition of COVID-19 vaccines should be modified as the virus continues evolving and vaccine protection wanes.
to examine how the composition of COVID-19 vaccines should be modified as the virus continues evolving and vaccine protection wanes.“As we’ve said since the early days of the pandemic, we will follow the science and adapt our own approaches as needed to help address COVID-19 as the virus evolves,” Pfizer CEO Albert Bourla said in a statement.
"We believe we have two very strong Omicron-adapted candidates that elicit a substantially higher immune response against Omicron than we’ve seen to date."The companies tested a vaccine candidate that targets the spike protein of the Omicron BA.1 variant, as well as a "bivalent" vaccine candidate that combined its Omicron-adapted vaccine with its vaccine for the original COVID strain.
The Omicron-adapted candidate given as a fourth booster dose increased neutralizing antibodies between 13.5 times and 19.6 times, depending on the dose administered. The "bivalent" vaccine candidate increased neutralizing antibodies between 9.1 times and 10.9 times against Omicron, depending on the dose administered.Preliminary studies demonstrate both Omicron-adapted candidates neutralize the subvariants Omicron BA.4 and BA.5 to a lesser extent than they do for BA.1, the companies said.
"We will therefore remain vigilant and are prepared to rapidly adapt our Omicron-adapted vaccine candidates to emerging sublineages if epidemiological and laboratory data suggest," Ugur Sahin, CEO and co-founder of BioNTech, said in a statement.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Moderna Says COVID Booster 'Potent' vs Newer Omicron VariantsModerna released study results today showing its new Omicron-specific booster increased antibodies against the coronavirus by a factor of 5, even against some of the newer and more worrisome variants.
Consulte Mais informação »
BA.5 Omicron Subvariant Spreading Quickly, Could Become Dominant Strain of COVID in U.S.: CDCAccording to the latest estimates from the Centers for Disease Control and Prevention, an omicron subvariant that has been the dominant strain of COVID-19 in the U.S. for more than a month is beginning to lose steam, and yet another variant of omicron is quickly gaining momentum.
Consulte Mais informação »
A New Covid Vaccine That’s Effective Against Omicron Could Hit The Market This YearI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health. I have master’s degrees in Biological Natural Sciences and the History and Philosophy of Science from Downing College, Cambridge University. Follow me on Twitter theroberthart or get in touch at rhartforbes.com
Consulte Mais informação »
CDC panel recommends Moderna two-dose Covid vaccine for kids ages 6 to 17CDC Director Dr. Rochelle Walensky is expected to sign off on the recommendation later Thursday,.
Consulte Mais informação »